Immune-boosting drug shows promise in ovarian cancer fight
NCT ID NCT02726997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced ovarian, fallopian tube, or primary peritoneal cancer. About 18 people with stage III or IV cancer will receive the combination. The main goal is to measure changes in immune markers in the tumor and blood, and to see if the treatment slows cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE SEROUS OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?